Luis Pow Sang

Luis Pow Sang

Auto-generated profile, based on publicly available information

Luis Pow Sang

A Uniformed Services University of the Health Sciences , Department of Medicine , Division of Immunology , Bethesda , MD , U.S.A.

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MMMirian Mendoza
Mirian Mendoza
ABAngela Ballesteros
Angela Ballesteros
QQQi Qiu
Qi Qiu
LSLuis Pow Sang
Luis Pow Sang
SSSoumya Shashikumar
Soumya Shashikumar
TBTeodor-D. Brumeanu
Teodor-D. Brumeanu
Pandemic outbreaks of influenza type A viruses have resulted in numerous fatalities around the globe. Since the conventional influenza vaccines (CIV) provide less than 20% protection for individuals with weak immune system, it has been considered that broadly cross-neutralizing antibodies may provide a better protection. Herein, we showed that a recently generated humanized mouse (DRAGA mouse; HLA-A2. HLA-DR4. Rag1KO. IL-2Rgc KO. NOD) that lacks the murine immune system and expresses a functional human immune system can be used to generate cross-reactive, human anti-influenza monoclonal antibodies (hu-mAb). DRAGA mouse was also found to be suitable for influenza virus infection, as it can clear a sub-lethal infection and sustain a lethal infection with PR8/A/34 influenza virus. The hu-mAbs were designed for targeting a human B-cell epitope (180WGIHHPPNSKEQ QNLY195) of hemagglutinin (HA) envelope protein of PR8/A/34 (H1N1) virus with high homology among seven influenza type A viruses. A single administration of HA180-195 specific hu-mAb in PR8-infected DRAGA mice significantly delayed the lethality by reducing the lung damage. The results demonstrated that DRAGA mouse is a suitable tool to (i) generate heterotype cross-reactive, anti-influenza human monoclonal antibodies, (ii) serve as a humanized mouse model for influenza infection, and (iii) assess the efficacy of anti-influenza antibody-based therapeutics for human use.

15 December 2016 in Malaria Research and Treatment
Verified
Journal Article
Open access
PDF file
MMMirian Mendoza
Mirian Mendoza
LSLuis Pow Sang
Luis Pow Sang
QQQi Qiu
Qi Qiu
SCSofia Casares
Sofia Casares
TBTeodor-D. Brumeanu
Teodor-D. Brumeanu
Background.Plasmodium yoelii17XNL is a nonlethal malaria strain in mice of different genetic backgrounds including the C57BL/6 mice (I-Ab/I-Enull) used in this study as a control strain. We have compared the trends of blood stage infection with the nonlethal murine strain ofP. yoelii17XNL malaria protozoan in immunocompetent Nonobese Diabetic (NOD) mice prone to type 1 diabetes (T1D) and C57BL/6 mice (control mice) that are not prone to T1D andself-cure theP. yoelii17XNL infection. Prediabetic NOD mice could not mount a protective antibody response to theP. yoelii17XNL-infected red blood cells (iRBCs), and they all succumbed shortly after infection. Our data suggest that the lack of anti-P. yoelii17XNL-iRBCs protective antibodies in NOD mice is a result of parasite-induced, Foxp3+T regulatory (Treg) cells able to suppress the parasite-specific antibody secretion.Conclusions. The NOD mouse model may help in identifying new mechanisms of B-cell evasion by malaria parasites. It may also serve as a more accurate tool for testing antimalaria therapeutics due to the lack of interference with a preexistentself-curing mechanism present in other mouse strains.